Food and drug administration (fda) for. Exel) today announced that its new drug application (nda) for zanzalintinib, in combination with atezolizumab (tecentriq®), has been. Find out how we're dedicated to giving more patients hope for the future.
Unveiling The Charismatic Zeeko Zaki A Rising Star In Entertainment
As a diverse, growing team, everyone at exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. Exelixis is a public company based in san francisco (united states), founded in 1994. Exelixis is expanding its global innovation engine to evolve how cancer is treated and deliver for physicians, patients and partners.
Home business exelixis announces fourth quarter and fiscal year 2024 financial results and provides corporate update
It operates as a developer of small molecule drugs for the treatment of cancer.
